Deal watch: Abbott boosts investment in NRF2 activators for reducing oxidative stress

Nature Reviews Drug Discovery

Volumn 11, Issue 2, 2012, Pages 96-

  Crunkhorn, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; TRANSCRIPTION FACTOR NRF2;

CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ENZYME ACTIVATION; ENZYME REGULATION; FUNDING; HUMAN; INVESTMENT; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANTIOXIDANTS; DRUG INDUSTRY; HUMANS; INFLAMMATION; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; OXIDATIVE STRESS;

EID: 84856465375     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3655     Document Type: Note

References (0)